Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention during the past three decades as a therapeutic target for the treatment of obesity and type 2 diabetes. Continuous improvement of the pharmacokinetic profile of GLP-1R agonists, starting from native hormone with a h...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Qiming, Akindehin, Seun E., Orsso, Camila E., Waldner, Richelle C., DiMarchi, Richard D., Müller, Timo D., Haqq, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921987/
https://www.ncbi.nlm.nih.gov/pubmed/35299971
http://dx.doi.org/10.3389/fendo.2022.838410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921987/
https://www.ncbi.nlm.nih.gov/pubmed/35299971
http://dx.doi.org/10.3389/fendo.2022.838410

Ejemplares similares